Oncorus: Going Viral To Beat Cancer
This week’s “2017 NEVYs Nominee Spotlight” is on Oncorus, a nominee for Hottest Early Stage Startup — Therapeutics. Today we’ll delve into why their work is so impactful to this region, and patients everywhere.
Germinating an idea
The approval in 2015 of Amgen’s IMLYGIC® (talimogene herparvovec), or T-VEC, established a clear regulatory path for the development of oncolytic virus immunotherapy. But how do you make T-VEC better?
Co-founded by industry veteran Mitchell Finer, Ph.D., former CSO of bluebird bio and a managing director at MPM Capital, Oncorus uses a next-generation oncolytic herpes simplex virus (oHSV) immunotherapy platform to improve upon first generation oncolytic viruses. Oncorus’s oHSV platform is based upon the work of renowned scientists Joseph Glorioso III, Ph.D., and Paola Grandi, Ph.D., both from the University of Pittsburgh and who serve on Oncorus’s Scientific Advisory Board. In addition to licensing certain patent rights from the University of Pittsburgh, the company has a number of other filed and licensed patents that make up its intellectual property portfolio.